Temozolomide

Title Average Ratingsort ascending
Metronomic schedule of temozolomide with conventional dose of cisplatin in metastatic melanoma. Sub-category: Melanoma Categor 90.00%
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytot..... 80.00%
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glio 80.00%
Different metronomic treatment schedules 80.00%
Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. 70.00%
Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer...... 60.00%
Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. 50.00%
Chemoradiotherapy in malignant glioma: standard of care and future directions. 50.00%
Inhibition of angiogenesis by non-toxic doses of temozolomide. 50.00%
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas ... 50.00%
Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. 50.00%
One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma 40.00%
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. 40.00%
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Onco 40.00%
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients .... 40.00%
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. 30.00%
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the 30.00%